eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, ...
Leadership
Davide Ruggero Ph.D.Founder
Co-Founder and Member of Clinical & Scientific Advisory Board
Kevan M. Shokat Ph.D.Founder
Co-Founder and Member of Clinical & Scientific Advisory Board